Cerebrovascular events after bevacizumab treatment: An early and severe complication

Neurocritical Care

Volumn 15, Issue 3, 2011, Pages 421-427

  Seet, Raymond C S ^a,b   Rabinstein, Alejandro A ^a   Lindell, Paul E ^a   Uhm, Joon H ^a   Wijdicks, Eelco F ^a  

^a MAYO CLINIC   (United States)

^b Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

Avastin; Bevacizumab; Hemorrhage; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CARBOPLATIN; IRINOTECAN; PACLITAXEL; PEMETREXED;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; ASTROCYTOMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FUNCTIONAL STATUS; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; ONSET AGE; PRIORITY JOURNAL; RANKIN SCALE; RECTUM CARCINOMA; RECURRENT CANCER; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TUMOR BLEEDING; VERTEBRAL ARTERY STENOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CEREBRAL ANGIOGRAPHY; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; DIFFUSION MAGNETIC RESONANCE IMAGING; DOMINANCE, CEREBRAL; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; ISCHEMIC ATTACK, TRANSIENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; NEUROLOGIC EXAMINATION; TOMOGRAPHY, X-RAY COMPUTED; VERTEBROBASILAR INSUFFICIENCY;

EID: 84856239169     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-011-9552-5     Document Type: Article

References (11)

1. Genentech IA. South San Francisco, CA, Genentech, Inc. 2009.
2. Margolin K, Gordon M. Shortening the infusion time of anticancer drugs: who will benefit? J Clin Oncol. 2007;25:2642-3. (Pubitemid 47123165)
3. Tanvetyanon T, Murtagh R, Bepler G. Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab. J Thorac Oncol. 2009;4:268-9.
4. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009;27:5255-61.
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
6. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer. 2010;116:3988-99.
7. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neurooncology. 2005;7: 134-53. (Pubitemid 40590514)
8. Rieger JBO, Muller K, Franz K, Steinbach J, Hattingen E. Bevacizumab- induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol. 2010;99:49-56.
9. Wong EH, Leung TW, Wong KS. Stroke caused by small vessel occlusion in a patient taking etoricoxib and thalidomide. J Neuroimaging. 2007;17:87-8. (Pubitemid 46066613)
10. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 1998;236:461-6. (Pubitemid 28269042)
11. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, Yuan J, Hefner C, Chartier C, Lee JS, Jiang S, Nayak NR, Kuypers FA, Ma L, Sundram U, Wu G, Garcia JA, Schrier SL, Maher JJ, Johnson RS, Yancopoulos GD, Mulligan RC, Kuo CJ. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med. 2006;12:793-800. (Pubitemid 44050069)